Kairos Pharma Acquires Oncology Asset from Celyn Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Kairos Pharma provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D.: "As we move toward the close of the second quarter, Kairos has been focused on adding some potentially impactful new development candidates to our existing pipeline. We announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics, Inc., a privately held biotechnology company backed by OrbiMed and Torrey Pines Investment. The Company will be acquiring the worldwide rights for a highly differentiated, clinical-stage oncology asset targeting non-small cell lung cancer and esophageal and gastric cancer: CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor... CL-741 will add to our already existing portfolio of exciting targets, including ENV-105, KROS-201, KROS-102 and ENV-205. We remain committed to seeing these therapeutics through the clinical system alongside our partners utilizing non-dilutive clinical funding as much as possible."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KAPA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KAPA
Wall Street analysts forecast KAPA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.457
Low
4.00
Averages
4.00
High
4.00
Current: 0.457
Low
4.00
Averages
4.00
High
4.00
No data
About KAPA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Its therapy includes antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its portfolio consists of seven drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301 and 401 and therapeutic agents ENV 105 and 205. KROS 101 is a small molecule that targets the glucocorticoid-induced tumor necrosis factor ligand-related (GITR) ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers. KROS 201 is a T cell therapy activated by dendritic cells to treat glioblastoma, a deadly and common brain cancer. ENV 105 drug seeks to address unmet medical needs in large markets of prostate and lung cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KAPA GOLD Inc. Successfully Holds Annual Shareholders Meeting
- Shareholder Voting Outcome: At the annual shareholders meeting held on June 18, 2026, KAPA GOLD INC. shareholders unanimously approved all items proposed by the Board and Management, reflecting strong support and trust in the company's governance.
- Board Re-election: Shareholders re-elected current board members David Paxton, George Nicholson, and Joanna-Josephine Pantazidou, ensuring stability and continuity in the company's leadership.
- Auditor Reappointment: The meeting also saw shareholders reappoint Davidson & Company LLP as auditors, a decision that will enhance financial transparency and bolster investor confidence.
- Stock Option Plan Approval: Shareholders approved the company's Stock Option Plan, aimed at attracting and retaining talent through incentive measures, thereby driving long-term growth and value enhancement for the company.
See More
Biotech Stocks Pre-Market Trading Insights
- Significant Pre-Market Gains: Picard Medical, Inc. (PMI) surged 34% to $0.36 in pre-market trading, indicating strong investor interest likely driven by positive clinical trial updates, which may attract further investment.
- Other Gaining Stocks: Connect Biopharma Holdings Limited (CNTB) rose 14% to $2.44, while LifeVantage Corporation (LFVN) increased 10% to $9.46, suggesting an improving investor sentiment in the biotech sector that could enhance overall industry performance.
- Pre-Market Decliners: TransCode Therapeutics, Inc. (RNAZ) fell 22% to $4.13, reflecting negative market reactions to recent news, which may lead investors to reassess its future prospects.
- Market Sentiment Impact: The overall pre-market trading indicates volatility in biotech stocks, prompting investors to closely monitor clinical trial results and corporate developments to make more informed investment decisions.
See More
Kairos Pharma to Hold Annual Shareholders Meeting Virtually
- Annual Meeting Announcement: Kairos Pharma, Ltd. has announced that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on June 29, 2026, with meeting materials to be mailed to shareholders post-filing with the SEC, ensuring compliance and transparency.
- Audit Report Emphasis: The financial statements included in the Annual Report for the year ended December 31, 2025, contain an audit report from an Independent Registered Public Accounting Firm, emphasizing that the statements were prepared under the assumption of the company's ongoing viability, reflecting confidence in future operations.
- Clinical Trial Developments: The company's lead candidate, ENV105, is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, aimed at addressing significant unmet medical needs, showcasing the company's innovative potential in oncology therapeutics.
- Cautionary Forward-Looking Statements: The press release includes cautionary forward-looking statements, alerting investors to potential risks and uncertainties, emphasizing that actual results may differ materially from expectations, reflecting the company's cautious approach to future developments.
See More
Schall Law Firm Investigates Kairos Pharma for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Kairos Pharma, focusing on potential violations of securities laws, including false or misleading statements that may affect investor rights.
- Investor Rights Protection: This investigation aims to protect investors, particularly those who have suffered losses due to the company's lack of transparency, by providing legal support to uphold their rights.
- Legal Consultation Services: Schall encourages affected shareholders to contact them for free legal consultations, helping investors understand their rights and possible legal avenues.
- Global Investor Representation: As a firm specializing in securities class action lawsuits and shareholder rights litigation, Schall Law Firm represents investors worldwide, committed to safeguarding their legitimate interests.
See More
Kairos Pharma Acquires CL-273 to Expand Oncology Pipeline
- Significant Market Opportunity: Kairos Pharma's acquisition of CL-273 targets a projected $16.2 billion EGFR-mutant lung cancer market by 2026, indicating a strategic positioning in the rapidly growing oncology therapeutics sector.
- Innovative Technical Advantage: CL-273 is an AI-designed pan-EGFR inhibitor specifically engineered for EGFR-mutant non-small cell lung cancer, expected to become a best-in-class asset addressing the urgent need for therapies against resistant mutations.
- Strengthened Partnerships: The collaboration with Celyn Therapeutics, backed by OrbiMed, enhances Kairos Pharma's research capabilities and is anticipated to accelerate the clinical development timeline for new therapies.
- Leadership Confidence: CEO John Yu stated that this acquisition is expected to be value-accretive, reflecting Kairos Pharma's long-term commitment and competitive edge in the oncology market.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
KAPA GOLD Inc. Successfully Holds Annual Shareholders Meeting
- Shareholder Voting Outcome: At the annual shareholders meeting held on June 18, 2026, KAPA GOLD INC. shareholders unanimously approved all items proposed by the Board and Management, reflecting strong support and trust in the company's governance.
- Board Re-election: Shareholders re-elected current board members David Paxton, George Nicholson, and Joanna-Josephine Pantazidou, ensuring stability and continuity in the company's leadership.
- Auditor Reappointment: The meeting also saw shareholders reappoint Davidson & Company LLP as auditors, a decision that will enhance financial transparency and bolster investor confidence.
- Stock Option Plan Approval: Shareholders approved the company's Stock Option Plan, aimed at attracting and retaining talent through incentive measures, thereby driving long-term growth and value enhancement for the company.
See More
Biotech Stocks Pre-Market Trading Insights
- Significant Pre-Market Gains: Picard Medical, Inc. (PMI) surged 34% to $0.36 in pre-market trading, indicating strong investor interest likely driven by positive clinical trial updates, which may attract further investment.
- Other Gaining Stocks: Connect Biopharma Holdings Limited (CNTB) rose 14% to $2.44, while LifeVantage Corporation (LFVN) increased 10% to $9.46, suggesting an improving investor sentiment in the biotech sector that could enhance overall industry performance.
- Pre-Market Decliners: TransCode Therapeutics, Inc. (RNAZ) fell 22% to $4.13, reflecting negative market reactions to recent news, which may lead investors to reassess its future prospects.
- Market Sentiment Impact: The overall pre-market trading indicates volatility in biotech stocks, prompting investors to closely monitor clinical trial results and corporate developments to make more informed investment decisions.
See More
Kairos Pharma to Hold Annual Shareholders Meeting Virtually
- Annual Meeting Announcement: Kairos Pharma, Ltd. has announced that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on June 29, 2026, with meeting materials to be mailed to shareholders post-filing with the SEC, ensuring compliance and transparency.
- Audit Report Emphasis: The financial statements included in the Annual Report for the year ended December 31, 2025, contain an audit report from an Independent Registered Public Accounting Firm, emphasizing that the statements were prepared under the assumption of the company's ongoing viability, reflecting confidence in future operations.
- Clinical Trial Developments: The company's lead candidate, ENV105, is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, aimed at addressing significant unmet medical needs, showcasing the company's innovative potential in oncology therapeutics.
- Cautionary Forward-Looking Statements: The press release includes cautionary forward-looking statements, alerting investors to potential risks and uncertainties, emphasizing that actual results may differ materially from expectations, reflecting the company's cautious approach to future developments.
See More
Schall Law Firm Investigates Kairos Pharma for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Kairos Pharma, focusing on potential violations of securities laws, including false or misleading statements that may affect investor rights.
- Investor Rights Protection: This investigation aims to protect investors, particularly those who have suffered losses due to the company's lack of transparency, by providing legal support to uphold their rights.
- Legal Consultation Services: Schall encourages affected shareholders to contact them for free legal consultations, helping investors understand their rights and possible legal avenues.
- Global Investor Representation: As a firm specializing in securities class action lawsuits and shareholder rights litigation, Schall Law Firm represents investors worldwide, committed to safeguarding their legitimate interests.
See More
Kairos Pharma Acquires CL-273 to Expand Oncology Pipeline
- Significant Market Opportunity: Kairos Pharma's acquisition of CL-273 targets a projected $16.2 billion EGFR-mutant lung cancer market by 2026, indicating a strategic positioning in the rapidly growing oncology therapeutics sector.
- Innovative Technical Advantage: CL-273 is an AI-designed pan-EGFR inhibitor specifically engineered for EGFR-mutant non-small cell lung cancer, expected to become a best-in-class asset addressing the urgent need for therapies against resistant mutations.
- Strengthened Partnerships: The collaboration with Celyn Therapeutics, backed by OrbiMed, enhances Kairos Pharma's research capabilities and is anticipated to accelerate the clinical development timeline for new therapies.
- Leadership Confidence: CEO John Yu stated that this acquisition is expected to be value-accretive, reflecting Kairos Pharma's long-term commitment and competitive edge in the oncology market.
See More
Significant Milestones in Biotech Sector This Week
- FDA Drug Approvals: Armata Pharmaceuticals' AP-SA02 received FDA's QIDP designation, granting five years of market exclusivity and paving the way for a Phase 3 trial in 2026, which is expected to significantly enhance the company's competitive edge in the antibiotic market.
- Weight Loss Innovation: Allurion Technologies' gastric balloon system gained FDA approval, offering a non-surgical weight loss option for patients with a BMI of 30-40, which is anticipated to expand the company's market share in the obesity sector.
- Acquisition Deal: Gilead Sciences is acquiring Arcellx for $115 per share, totaling $7.8 billion, a move that will strengthen Gilead's position in cell therapy and enhance its collaboration with Kite Pharma.
- Clinical Trial Developments: Novo Nordisk's CagriSema missed key goals in its trial against Zepbound, although it demonstrated a favorable safety profile, which may influence future market strategies.
See More
